



Bruno Medeiros

Adjunct Clinical Associate Professor, Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Stanford Comprehensive Cancer Center**

875 Blake Wilbur Dr Rm 2329

MC 6560

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 724-5203

Bio

BIO

Bruno C. Medeiros, MD is associate professor of medicine. Dr. Medeiros graduated from the Universidade Federal do Parana with a medical degree, in 1998. He completed his post-graduate training at the University of Colorado in Denver and the Princess Margaret Hospital in Toronto (Acute leukemia fellowship). Dr. Medeiros' clinical interests include management of advanced hematologic malignancies, including AML, ALL, MDS and CML. His clinical research interest focuses on the development of novel therapeutic regimens for patients with acute leukemia, with special interest in the development of novel therapeutic strategies for patients with acute myeloid leukemia. He is the leader in several institutional investigator initiated clinical trials, active investigator in collaborative multi-institutional clinical studies and an active member of the SWOG acute leukemia panel. Dr. Medeiros has authored more than 120 peer-reviewed manuscripts. Dr. Medeiros has served as the track leader for ASCO meeting Leukemia, Myelodysplasia and Transplantation scientific review subcommittee, he functions as the Associate Editor of the Leukemia Panel for Cancer.Net, he is a member of the editorial board for Leukemia Research and serves as a reviewer for several specialized journals, such as Blood, Leukemia, Haematologica and Cancer, among others. Previously, he served as the director of the inpatient hematology service and also director of Cancer Center ITA services at Stanford Comprehensive Cancer Center.

CLINICAL FOCUS

- Cancer > Hematology
- Hematology
- Acute leukemia

ADMINISTRATIVE APPOINTMENTS

- Panel Member Multiple Myeloma Committee, National Comprehensive Cancer Network, (2007-2011)
- Acute Leukemia Panel Member, Southwest Oncology Group (SWOG), (2007-2016)
- Panel member adult oncology committee, National comprehensive cancer network, (2010-2016)
- Director, Director of Infusion Services (ITA), (2015-2016)
- Director, Stanford Hospital Hematology Inpatient service, (2011-2016)

PROFESSIONAL EDUCATION

- Fellowship: University of Colorado Denver Hematology and Oncology Fellowship (2005) CO
- Fellowship, Acute leukemia , Princess Margaret Hospital - University of Toronto (2006)
- Board Certification: Hematology, American Board of Internal Medicine (2006)
- Residency: University of Colorado Health Science Center (2002) CO
- Internship: University of Connecticut Health Center (2000) CT
- Medical Education: University Federal Do Parana (1998) Brazil

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My clinical activities combine the development of novel therapeutic modalities, translational research activities and epidemiological study of acute leukemia. My special focus is on the development of better, patient tailored therapies for young and elderly patients with acute leukemia.

CLINICAL TRIALS

- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive, Not Recruiting
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia, Not Recruiting
- A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis, Not Recruiting
- A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML), Not Recruiting
- A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL), Not Recruiting
- A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects # 65 Years With Newly-Diagnosed Acute Myeloid Leukemia, Not Recruiting
- A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I), Not Recruiting
- A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL, Not Recruiting
- A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome, Not Recruiting
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML, Not Recruiting
- An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study, Not Recruiting
- Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS, Not Recruiting
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia, Not Recruiting
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia, Not Recruiting
- Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia, Not Recruiting
- Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone, Not Recruiting
- Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML), Not Recruiting
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia, Not Recruiting
- Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML, Not Recruiting
- CONTROLLED MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial, Not Recruiting
- CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome, Not Recruiting

- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia, Not Recruiting
- Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Not Recruiting
- Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, Not Recruiting
- Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents, Not Recruiting
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies, Not Recruiting
- Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia, Not Recruiting
- Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis, Not Recruiting
- Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas, Not Recruiting
- Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients, Not Recruiting
- Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS), Not Recruiting
- Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET), Not Recruiting
- Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512), Not Recruiting
- Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients, Not Recruiting
- Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting
- Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting
- Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting
- Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia, Not Recruiting
- MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting
- Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant, Not Recruiting
- MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia, Not Recruiting
- Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma, Not Recruiting
- Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma, Not Recruiting
- Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML), Not Recruiting
- Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation, Not Recruiting
- Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia, Not Recruiting
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM, Not Recruiting
- Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia, Not Recruiting
- Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia, Not Recruiting
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia, Not Recruiting
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia, Not Recruiting
- S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Not Recruiting
- S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia, Not Recruiting
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML), Not Recruiting
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET), Not Recruiting
- Safety and Efficacy Study of Pracinostat With Azacitidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML), Not Recruiting
- Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease, Not Recruiting
- Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL, Not Recruiting

- Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia, Not Recruiting
- Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma, Not Recruiting
- Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Not Recruiting
- Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older, Not Recruiting
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma, Not Recruiting
- Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy, Not Recruiting
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia, Not Recruiting
- Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML), Not Recruiting
- To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS., Not Recruiting
- Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML, Not Recruiting

Publications

PUBLICATIONS

- **Functional genomic landscape of acute myeloid leukaemia.** *Nature*
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A. R., Traer, E., Abel, M., Agarwal, A., Blucher, A., Borate, et al
2018
- **CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D. n., Solomon, S. R., Stone, R. M., Bixby, D. L., Kolitz, et al
2018: JCO2017776112
- **relapsed or refractory acute myeloid leukemia.** *Blood*
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., Kantarjian, H. M., Collins, R., Patel, et al
2017
- **Novel Therapeutics in Acute Myeloid Leukemia.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting*
DiNardo, C. D., Stone, R. M., Medeiros, B. C.
2017; 37: 495-503
- **Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.** *The New England journal of medicine*
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K. n., Geyer, S. n., Bloomfield, C. D., Thiede, C. n., Prior, T. W., Döhner, K. n., Marcucci, G. n., Lo-Coco, F. n., Klisovic, R. B., Wei, et al
2017
- **Isocitrate dehydrogenase mutations in myeloid malignancies.** *Leukemia*
Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., SWORDS, R.
2016
- **Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.** *Oncotarget*
Østgård, L. S., Nørgaard, M. n., Sengeløv, H. n., Medeiros, B. C., Kjeldsen, L. n., Overgaard, U. M., Severinsen, M. T., Marcher, C. W., Jensen, M. K., Nørgaard, J. M.
2016
- **Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

- Granfeldt Østgård, L. S., Medeiros, B. C., Sengeløv, H. n., Nørgaard, M. n., Andersen, M. K., Dufva, I. H., Friis, L. S., Kjeldsen, E. n., Marcher, C. W., Preiss, B. n., Severinsen, M. n., Nørgaard, J. M.
2015
- **Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.** *Proceedings of the National Academy of Sciences of the United States of America*
Corces-Zimmerman, M. R., Hong, W., Weissman, I. L., Medeiros, B. C., Majeti, R.
2014; 111 (7): 2548-2553
 - **Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia** *LEUKEMIA*
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., Bhattacharya, S., Zehnder, J., Liedtke, M., Gotlib, J. R., Coutre, S., Berube, C., Melnick, et al
2012; 26 (5): 893-901
 - **Cytarabine Dose for Acute Myeloid Leukemia** *NEW ENGLAND JOURNAL OF MEDICINE*
Medeiros, B. C., Othus, M., Appelbaum, F. R.
2011; 364 (22): 2167-2168
 - **Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience** *BLOOD*
Medeiros, B. C., Othus, M., Fang, M., Roulston, D., Appelbaum, F. R.
2010; 116 (13): 2224-2228
 - **A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.** *Leukemia*
Garcia-Manero, G., Podoltsev, N. A., Othus, M., Pagel, J. M., Radich, J. P., Fang, M., Rizzieri, D. A., Marcucci, G., Strickland, S. A., Litzow, M. R., Savoie, M. L., Medeiros, B. C., Sekeres, et al
2023
 - **Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms**
Gauthier, J., Furtuna, B., Mangiavacchi, J., Gholami, S., Ferres, J., Dodhia, R., Fathi, A. T., Brunner, A. M., Gerds, A. T., Sekeres, M. A., Medeiros, B. C., Wang, E. S., Shami, et al
AMER SOC HEMATOLOGY.2022: 5254-5257
 - **An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients.** *Blood*
Sorrer, M. L., Gooley, T. A., Storer, B. E., Gerds, A. T., Sekeres, M. A., Medeiros, B. C., Wang, E. S., Shami, P. J., Adekola, K. U., Luger, S. M., Baer, M. R., Rizzieri, D. A., Wildes, et al
2022
 - **Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.** *Leukemia*
Jahn, N., Jahn, E., Saadati, M., Bullinger, L., Larson, R. A., Ottone, T., Amadori, S., Prior, T. W., Brandwein, J. M., Appelbaum, F. R., Medeiros, B. C., Tallman, M. S., Ehninger, et al
2022
 - **Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study.** *Leukemia & lymphoma*
Maeng, C. V., Christiansen, C. F., Liu, K. D., Kamper, P., Christensen, S., Medeiros, B. C., Ostgard, L. S.
2022: 1-11
 - **Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia.** *Leukemia & lymphoma*
Miranti, E., Ho, D. Y., Enriquez, K., Subramanian, A. K., Medeiros, B. C., Epstein, D. J.
2022: 1-7
 - **Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.** *Blood advances*
Gerds, A. T., Scott, B. L., Greenberg, P. L., Lin, T. L., Pollyea, D. A., Verma, A. K., Dail, M., Feng, Y., Green, C., Ma, C., Medeiros, B. C., Yan, M., Yousefi, et al
1800
 - **Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.** *Blood*
Sorrer, M. L., Storer, B. E., Fathi, A. T., Brunner, A., Gerds, A. T., Sekeres, M. A., Mukherjee, S., Medeiros, B. C., Wang, E. S., Vachhani, P., Shami, P. J., Peña, E., Elsayy, et al
2021; 138 (5): 387-400

- **Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.** *Leukemia*
Rucker, F. G., Du, L., Luck, T. J., Benner, A., Krzykalla, J., Gathmann, I., Voso, M. T., Amadori, S., Prior, T. W., Brandwein, J. M., Appelbaum, F. R., Medeiros, B. C., Tallman, et al
2021
- **Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.**
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., Liedtke, M.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.** *Leukemia*
Larson, R. A., Mandrekar, S. J., Huebner, L. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Dohner, K., Marcucci, G., Voso, M. T., Klisovic, et al
2021
- **Plasma Microbial Cell-free DNA Next Generation Sequencing in the Diagnosis and Management of Febrile Neutropenia.** *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*
Benamu, E. n., Gajurel, K. n., Anderson, J. N., Lieb, T. n., Gomez, C. A., Seng, H. n., Aquino, R. n., Hollemon, D. n., Hong, D. K., Blauwkamp, T. A., Kertesz, M. n., Blair, L. n., Bollyky, et al
2021
- **Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.** *Blood*
Sorrer, M. L., Storer, B. E., Fathi, A. T., Brunner, A. M., Gerds, A. T., Sekeres, M. A., Mukherjee, S. n., Medeiros, B. C., Wang, E. S., Vachhani, P. n., Shami, P. J., Peña, E. n., Elsayay, et al
2021
- **Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.** *Blood advances*
Voso, M. T., Larson, R. A., Jones, D., Marcucci, G., Prior, T., Krauter, J., Heuser, M., Lavorgna, S., Nomdedeu, J., Geyer, S. M., Walker, A., Wei, A. H., Sierra, et al
2020; 4 (19): 4945–54
- **Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients**
Sorrer, M., Storer, B., Fathi, A., Brunner, A., Gerds, A., Sekeres, M., Medeiros, B., Wang, E., Shami, P., Adekola, K., Luger, S., Baer, M., Rizzieri, et al
CIG MEDIA GROUP, LP.2020: S185
- **Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.** *Journal of managed care & specialty pharmacy*
Pandya, B. J., Chen, C., Medeiros, B. C., McGuinness, C. B., Wilson, S. D., Walsh, E. H., Wade, R. L.
2020: 1–11
- **Functional characterization of two rare BCR-FGFR1+ leukemias.** *Cold Spring Harbor molecular case studies*
Barnes, E. J., Leonard, J. n., Medeiros, B. n., Druker, B. J., Tognon, C. E.
2020
- **Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.** *Leukemia & lymphoma*
Azizi, A. n., Ediriwickrema, A. n., Dutta, R. n., Patel, S. A., Shomali, W. n., Medeiros, B. n., Iberri, D. n., Gotlib, J. n., Mannis, G. n., Greenberg, P. n., Majeti, R. n., Zhang, T. n.
2020: 1–8
- **Single-cell mutational profiling enhances the clinical evaluation of AML MRD.** *Blood advances*
Ediriwickrema, A. n., Aleshin, A. n., Reiter, J. G., Corces, M. R., Köhnke, T. n., Stafford, M. n., Liedtke, M. n., Medeiros, B. C., Majeti, R. n.
2020; 4 (5): 943–52
- **Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.** *JCO oncology practice*
Pagel, J. M., Othus, M. n., Garcia-Manero, G. n., Fang, M. n., Radich, J. P., Rizzieri, D. A., Marcucci, G. n., Strickland, S. A., Litzow, M. R., Savoie, M. L., Spellman, S. R., Confer, D. L., Chell, et al
2020: JOP1900133
- **Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.** *American journal of hematology*
Garcia, J. S., Bhatt, S., Fell, G., Sperling, A. S., Burgess, M., Keshishian, H., Yilma, B., Brunner, A., Neuberger, D., Carr, S. A., Ebert, B. L., Ballen, K., Stone, et al

2019

- **Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study.** *Clinical epidemiology*
Tøstesen, M., Nørgaard, M., Nørgaard, J. M., Medeiros, B. C., Marcher, C. W., Overgaard, U. M., Severinsen, M. T., Schoellkopf, C., Østgård, L. S.
2019; 11: 769-780
- **Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis.** *Blood*
Zhang, H., Wilmot, B., Bottomly, D., Dao, K. T., Stevens, E., Eide, C. A., Khanna, V., Rofelty, A., Savage, S., Reister-Schultz, A., Long, N., White, L., Carlos, et al
2019
- **Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. A., Pollyea, D. A.
2019; 94 (7): 803–11
- **Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.** *Advances in therapy*
Pandya, B. J., Chen, C., Medeiros, B. C., McGuinness, C. B., Wilson, S., Horvath Walsh, L. E., Wade, R. L.
2019
- **Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia.** *Oncology and therapy*
Horvath Walsh, L. E., Rider, A., Piercy, J., Pike, J., Wilson, S., Pandya, B. J., Medeiros, B. C.
2019; 7 (1): 67-81
- **Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia** *ONCOLOGY AND THERAPY*
Walsh, L., Rider, A., Piercy, J., Pike, J., Wilson, S., Pandya, B. J., Medeiros, B. C.
2019; 7 (1): 67–81
- **Addressing the room for improvement in management of acute promyelocytic leukemia** *EUROPEAN JOURNAL OF HAEMATOLOGY*
Norgaard, J. M., Friis, L. S., Kristensen, J. S., Severinsen, M. T., Molle, I., Marcher, C. W., Moller, P., Schoellkopf, C., Nielsen, O. J., Preiss, B. S., Andersen, M. K., Kjeldsen, E., Medeiros, et al
2019; 102 (6): 479–85
- **Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial** *BRITISH JOURNAL OF HAEMATOLOGY*
Bixby, D., Noppeney, R., Lin, T. L., Cortes, J., Krauter, J., Yee, K., Medeiros, B. C., Kraemer, A., Assouline, S., Fiedler, W., Dimier, N., Simmons, B. P., Riehl, et al
2019; 185 (3): 595–98
- **Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.** *American journal of hematology*
Medeiros, B. C., Chan, S. M., Daver, N. G., Jonas, B. A., Pollyea, D. A.
2019
- **Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey** *CURRENT MEDICAL RESEARCH AND OPINION*
Medeiros, B. C., Pandya, B. J., Hadfield, A., Pike, J., Wilson, S., Mueller, C., Bui, C. N., Flanders, S. C., Rider, A., Walsh, L.
2019; 35 (5): 927–35
- **Addressing the Room for Improvement in Management of Acute Promyelocytic Leukemia.** *European journal of haematology*
Norgaard, J. M., Friis, L. S., Kristensen, J. S., Severinsen, M. T., Molle, I., Marcher, C. W., Moller, P., Schoellkopf, C., Nielsen, O. J., Preiss, B. S., Andersen, M. K., Kjeldsen, E., Medeiros, et al
2019
- **The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)** *LEUKEMIA RESEARCH*
Medeiros, B. C., Othus, M., Tallman, M. S., Sun, Z., Fernandez, H. F., Rowe, J. M., Lazarus, H. M., Appelbaum, F. R., Luger, S. M., Litzow, M. R., Erba, H. P.
2019; 78: 29–33
- **Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study**

Sorrer, M. L., Storer, B. E., Gerds, A. T., Medeiros, B. C., Shami, P. J., Galvin, J. P., Adekola, K. U., Luger, S. M., Baer, M. R., Rizzieri, D. A., Wildes, T. M., Wang, E. S., Faderl, et al
ELSEVIER SCIENCE INC.2019

- **Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study** *BLOOD ADVANCES*
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., Patel, P., Maness-Harris, L., Stuart, et al
2019; 3 (4): 508–18
- **Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.** *Blood advances*
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., Patel, P., Maness-Harris, L., Stuart, et al
2019; 3 (4): 508–18
- **Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey.** *Current medical research and opinion*
Medeiros, B. C., Pandya, B. J., Hadfield, A., Pike, J., Wilson, S., Mueller, C., Bui, C. N., Flanders, S. C., Rider, A., Horvath, L. E.
2019; 1
- **The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).** *Leukemia research*
Medeiros, B. C., Othus, M., Tallman, M. S., Sun, Z., Fernandez, H. F., Rowe, J. M., Lazarus, H. M., Appelbaum, F. R., Luger, S. M., Litzow, M. R., Erba, H. P.
2019; 78: 29–33
- **Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.** *PLoS one*
Narayan, R. n., Olsson, N. n., Wagar, L. E., Medeiros, B. C., Meyer, E. n., Czerwinski, D. n., Khodadoust, M. S., Zhang, L. n., Schultz, L. n., Davis, M. M., Elias, J. E., Levy, R. n.
2019; 14 (7): e0219547
- **Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study** *CLINICAL EPIDEMIOLOGY*
Tostesen, M., Norgaard, M., Norgaard, J., Medeiros, B. C., Marcher, C., Overgaard, U., Severinsen, M., Schoellkopf, C., Ostgard, L.
2019; 11: 769–80
- **Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.** *Blood*
Döhner, K. n., Thiede, C. n., Jahn, N. n., Panina, E. n., Gambietz, A. n., Larson, R. A., Prior, T. W., Marcucci, G. n., Jones, D. n., Krauter, J. n., Heuser, M. n., Voso, M. T., Ottone, et al
2019
- **Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.** *Leukemia research*
DeAngelo, D. J., Walker, A. R., Schlenk, R. F., Sierra, J. n., Medeiros, B. C., Ocio, E. M., Röllig, C. n., Strickland, S. A., Thol, F. n., Valera, S. Z., Dasgupta, K. n., Berkowitz, N. n., Stuart, et al
2019; 85: 106197
- **Is there a standard of care for relapsed AML?** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
Medeiros, B. C.
2018; 31 (4): 384–86
- **Is there a standard of care for relapsed AML?** *Best practice & research. Clinical haematology*
Medeiros, B. C.
2018; 31 (4): 384–86
- **Single-Cell Mutational Profiling Describes the Molecular Heterogeneity of Clonal Evolution in MDS during Therapy and Relapse**
Aleshin, A., Durruthy-Durruthy, R., Medeiros, B. C., Eastburn, D. J., Greenberg, P. L.
AMER SOC HEMATOLOGY.2018
- **PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis**
Gerds, A. T., Scott, B. L., Greenberg, P. L., Khaled, S. K., Lin, T. L., Pollyea, D. A., Verma, A., Dail, M., Green, C., Ma, C., Medeiros, B. C., Phuong, P., Wenger, et al
AMER SOC HEMATOLOGY.2018
- **Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study**

Sorrer, M. L., Storer, B. E., Gerds, A. T., Medeiros, B. C., Shami, P. J., Galvin, J. P., Adekola, K. U., Luger, S., Baer, M. R., Rizzieri, D. A., Wildes, T. M., Wang, E. S., Faderl, et al

AMER SOC HEMATOLOGY.2018

- **Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603)**
Ruecker, F. G., Du, L., Blaette, T. J., Benner, A., Krzykalla, J., Gathmann, I., Larson, R. A., Lo-Coco, F., Amadori, S., Prior, T. W., Brandwein, J. M., Appelbaum, F. R., Medeiros, et al
AMER SOC HEMATOLOGY.2018
- **Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)**
Jahn, N., Panina, E., Bullinger, L., Dolnik, A., Herzig, J., Blaette, T. J., Benner, A., Krzykalla, J., Gathmann, I., Larson, R. A., Lo-Coco, F., Amadori, S., Prior, et al
AMER SOC HEMATOLOGY.2018
- **Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML)**
Medeiros, B. C., Satram-Hoang, S., Momin, F., Parisi, M.
AMER SOC HEMATOLOGY.2018
- **Longer Distance to a Specialized Treatment Center Does Not Adversely Affect Access to Treatment or Outcome in Acute Myeloid Leukemia: A National Population-Based Cohort Study**
Tostesen, M., Norgaard, J. M., Norgaard, M., Medeiros, B. C., Marcher, C., Overgaard, U., Schollkopf, C., Severinsen, M., Oestgaard, L.
AMER SOC HEMATOLOGY.2018
- **Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy**
Voso, M., Larson, R. A., Prior, T., Marcucci, G., Jones, D., Krauter, J., Heuser, M., Lavorgna, S., Nomdedeu, J., Geyer, S. M., Klisovic, R., Wei, A. H., Sierra, et al
AMER SOC HEMATOLOGY.2018
- **Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study**
Sorrer, M. L., Storer, B. E., Gerds, A. T., Medeiros, B. C., Shami, P. J., Galvin, J. P., Adekola, K. U., Luger, S., Baer, M. R., Rizzieri, D. A., Wildes, T. M., Wang, E. S., Faderl, et al
AMER SOC HEMATOLOGY.2018
- **Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse**
Aleshin, A., Durruthy-Durruthy, R., Corces, M., Stafford, M., Liedtke, M., Medeiros, B. C., Eastburn, D. J., Majeti, R.
AMER SOC HEMATOLOGY.2018
- **Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia**
Elsayed, S., Storer, B. E., Medeiros, B. C., Asslan, M., Lynch, Y., Nyland, J. E., Becker, P. S., Percival, M. M., Estey, E. H., Sorror, M. L.
AMER SOC HEMATOLOGY.2018
- **Increase in Chemotherapy Use and Associated Survival Benefit Among Medicare-Aged Patients with Acute Myeloid Leukemia (AML)**
Medeiros, B. C., Satram-Hoang, S., Momin, F., Parisi, M.
AMER SOC HEMATOLOGY.2018
- **Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia**
Garcia, J. S., Bhatt, S., Fell, G., Blonquist, T. M., Taw, J., Iberri, D., Letai, A., Medeiros, B. C.
AMER SOC HEMATOLOGY.2018
- **The Relationship between Age and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a Cohort of Older Patients with Acute Myeloid Leukemia (AML)**
Medeiros, B. C., Satram-Hoang, S., Momin, F., Parisi, M.
AMER SOC HEMATOLOGY.2018
- **NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study.** *Cancer management and research*
Østgård, L. S., Nørgaard, M., Pedersen, L., Østgård, R., Friis, L. S., Schöllkopf, C., Severinsen, M. T., Marcher, C. W., Medeiros, B. C., Jensen, M. K.
2018; 10: 5043-5051
- **Functional genomic landscape of acute myeloid leukaemia** *NATURE*
Tyner, J. W., Tognon, C. E., Bottomly, D., Wilmot, B., Kurtz, S. E., Savage, S. L., Long, N., Schultz, A., Traer, E., Abel, M., Agarwal, A., Blucher, A., Borate, et al

2018; 562 (7728): 526-+

- **Chemotherapy based combinations in AML: Time to take a step back?** *LEUKEMIA RESEARCH*
Medeiros, B. C.
2018; 73: 39-40
- **Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.** *British journal of haematology*
Bixby, D., Noppeney, R., Lin, T. L., Cortes, J., Krauter, J., Yee, K., Medeiros, B. C., Kramer, A., Assouline, S., Fiedler, W., Dimier, N., Simmons, B. P., Riehl, et al
2018
- **CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., Stone, R. M., Bixby, D. L., Koltitz, et al
2018; 36 (26): 2684-+
- **Chemotherapy based combinations in AML: Time to take a step back?** *Leukemia research*
Medeiros, B. C.
2018; 73: 39-40
- **Non-zero-sum game of transfusions: EOL in leukemia** *BLOOD*
Medeiros, B. C.
2018; 132 (7): 676-+
- **Recurrent drug sensitivity patterns in myelodysplastic syndrome patients are recapitulated by ex vivo drug response profiling**
Aleshin, A., Medeiros, B. C., Kamble, S., Heiser, D., Santaguida, M., Prashad, S., Greenberg, P. L.
AMER ASSOC CANCER RESEARCH.2018
- **Single-cell mutational profiling of clonal evolution in myelodysplastic syndromes (MDS) during therapy and disease progression**
Aleshin, A., Greenberg, P. L., Medeiros, B. C., Heiser, D., Santaguida, M., Prashad, S., Durruthy-Durruthy, R., Eastburn, D. J.
AMER ASSOC CANCER RESEARCH.2018
- **Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study** *BLOOD*
Ostgard, L., Norgaard, M., Medeiros, B. C., Severinsen, M., Friis, L., Marcher, C., Schoellkopf, C., Norgaard, J.
2018; 131 (24): 2730-33
- **Epidemiology and impact of preceding or underlying disease in secondary acute myeloid leukemia** *HEMASPHERE*
Ostgard, L., Medeiros, B. C.
2018; 2: 153-55
- **Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).**
Lin, T. L., Medeiros, B. C., Uy, G. L., Newell, L., Ritchie, E. K., Stuart, R. K., Strickland, S., Hogge, D., Solomon, S. R., Stone, R. M., Bixby, D. L., Koltitz, J. E., Schiller, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **National Survey of Pathologists on the Application of Ancillary Testing in the Diagnosis of Acute Myeloid Leukemia**
Hasserjian, R., Altman, J., Denzen, E., Block, A., Klepin, H., Medeiros, B., Noe, A., Scales, W., Tallman, M., Wiley, K., Burns, L.
NATURE PUBLISHING GROUP.2018: 520
- **National Survey of Pathologists on the Application of Ancillary Testing in the Diagnosis of Acute Myeloid Leukemia**
Hasserjian, R., Altman, J., Denzen, E., Block, A., Klepin, H., Medeiros, B., Noe, A., Scales, W., Tallman, M., Wiley, K., Burns, L.
NATURE PUBLISHING GROUP.2018: 520
- **Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin**
Lin, T. L., Uy, G. L., Wieduwilt, M. J., Newell, L. F., Stuart, R. K., Medeiros, B. C., Schiller, G. J., Rubenstein, S., Stock, W., Warlick, E., Foster, M., Bixby, D. L., Podoltsev, et al
ELSEVIER SCIENCE INC.2018: S228-S229

- **Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.** *Blood reviews*
Medeiros, B. C., Possick, J. n., Fradley, M. n.
2018
- **NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study** *CANCER MANAGEMENT AND RESEARCH*
Ostgard, L., Norgaard, M., Pedersen, L., Ostgard, R., Friis, L., Schollkopf, C., Severinsen, M., Marcher, C., Medeiros, B. C., Jensen, M.
2018; 10: 5043–51
- **A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.** *International journal of hematology*
Dinner, S. n., Dunn, T. J., Price, E. n., Coutré, S. E., Gotlib, J. n., Berube, C. n., Kaufman, G. P., Medeiros, B. C., Liedtke, M. n.
2018
- **A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.** *Clinical lymphoma, myeloma & leukemia*
Medeiros, B. C., Tanaka, T. N., Balaian, L. n., Bashey, A. n., Guzdar, A. n., Li, H. n., Messer, K. n., Ball, E. D.
2018
- **Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.** *British journal of haematology*
Østgård, L. S., Nørgaard, M. n., Pedersen, L. n., Østgård, R. D., Medeiros, B. C., Overgaard, U. M., Schöllkopf, C. n., Severinsen, M. n., Marcher, C. W., Jensen, M. K.
2018
- **Interpretation of clinical endpoints in trials of acute myeloid leukemia.** *Leukemia research*
Medeiros, B. C.
2018; 68: 32–39
- **Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).** *Leukemia research*
Advani, A. S., Li, H. n., Michaelis, L. C., Medeiros, B. C., Liedtke, M. n., List, A. F., O'Dwyer, K. n., Othus, M. n., Erba, H. P., Appelbaum, F. R.
2018; 67: 17–20
- **Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)**
Kolitz, J., Strickland, S., Cortes, J., Hogge, D., Lancet, J., Goldberg, S., Chung, K., Ryan, R., Chiarella, M., Louie, A., Stuart, R., Medeiros, B.
CIG MEDIA GROUP, LP.2017: S287
- **Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)**
Medeiros, B., Hogge, D., Newell, L., Bixby, D., Solomon, S., Strickland, S., Lin, T., Erba, H., Powell, B., Podoltsev, N., Ryan, R., Chiarella, M., Louie, et al
CIG MEDIA GROUP, LP.2017: S286
- **Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).**
Kolitz, J. E., Strickland, S., Cortes, J. E., Hogge, D., Lancet, J. E., Goldberg, S. L., Chung, K. C., Ryan, R., Chiarella, M., Louie, A., Stuart, R. K., Medeiros, B. C.
AMER SOC CLINICAL ONCOLOGY.2017
- **Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.**
Takahashi, K., Abaza, Y., Atallah, E. L., Medeiros, B. C., Khal, S., Arellano, M., Patnaik, M., Ghalie, R., Garcia-Manero, G.
AMER SOC CLINICAL ONCOLOGY.2017
- **Quality of life of acute myeloid leukemia patients in a real-world setting.**
Pandya, B. J., Hadfield, A., Medeiros, B. C., Wilson, S., Bui, C. N., Bailey, T., Flanders, S., Rider, A., Horvath, L. E.
AMER SOC CLINICAL ONCOLOGY.2017
- **Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.**
Stein, E. M., Dinardo, C., Pollyea, D., Fathi, A., Roboz, G. J., Altman, J. K., Stone, R. M., Flinn, I., Kantarjian, H. M., Collins, R., Patel, M. R., Stein, A., Sekeres, et al

AMER SOC CLINICAL ONCOLOGY.2017

- **Real-world prescribing patterns in acute myeloid leukemia in the United States.**
Medeiros, B. C., Pandya, B. J., Hadfield, A., Wilson, S., Mueller, C., Bailey, T., Flanders, S., Horvath, L. E., Rider, A.
AMER SOC CLINICAL ONCOLOGY.2017
- **Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).**
Medeiros, B. C., Hogge, D., Newell, L. F., Bixby, D. L., Solomon, S. R., Strickland, S., Lin, T. L., Erba, H., Powell, B. L., Podoltsev, N., Ryan, R., Chiarella, M., Louie, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Novel Therapeutics in Acute Myeloid Leukemia.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*
DiNardo, C. D., Stone, R. M., Medeiros, B. C.
2017: 495–503
- **Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia** *CELL REPORTS*
Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., Druker, B. J., Bagby, G. C., McWeeny, et al
2017; 18 (13): 3204-3218
- **Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial**
Lancet, J., Uy, G. L., Cortes, J., Newell, L. F., Lin, T. L., Ritchie, E., Stuart, R., Strickland, S., Hogge, D., Solomon, S. R., Stone, R. M., Bixby, D. L., Kolitz, et al
ELSEVIER SCIENCE INC.2017: S31–S32
- **Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.** *Blood cancer journal*
Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., ANWER, F., Hua, Z., Stein, H., Faessel, H., Sedarati, F., Dezube, B. J., Giles, F. J., Medeiros, et al
2017; 7 (2)
- **Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.** *Blood cancer journal*
Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., ANWER, F., Hua, Z., Stein, H., Faessel, H., Sedarati, F., Dezube, B. J., Giles, F. J., Medeiros, et al
2017; 7 (2)
- **Isocitrate dehydrogenase mutations in myeloid malignancies** *LEUKEMIA*
Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., SWORDS, R.
2017; 31 (2): 272-281
- **A Study of Disseminated Intravascular Coagulation in Acute Leukemia Reveals Markedly Elevated D-Dimer Levels Are a Sensitive Indicator of Acute Promyelocytic Leukemia**
Oak, J., Shahmarvand, N., Alcasid, M., Cascio, M., Goodman, E., Medeiros, B., Arber, D. A., Zehnder, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 367A
- **A Study of Disseminated Intravascular Coagulation in Acute Leukemia Reveals Markedly Elevated D-Dimer Levels Are a Sensitive Indicator of Acute Promyelocytic Leukemia**
Oak, J., Shahmarvand, N., Alcasid, M., Cascio, M., Goodman, E., Medeiros, B., Arben, D. A., Zehnder, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 367A
- **A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia.** *International journal of laboratory hematology*
Shahmarvand, N. n., Oak, J. S., Cascio, M. J., Alcasid, M. n., Goodman, E. n., Medeiros, B. C., Arber, D. A., Zehnder, J. L., Ohgami, R. S.
2017
- **Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.** *Proceedings of the National Academy of Sciences of the United States of America*
Kurtz, S. E., Eide, C. A., Kaempfer, A. n., Khanna, V. n., Savage, S. L., Rofelty, A. n., English, I. n., Ho, H. n., Pandya, R. n., Bolosky, W. J., Poon, H. n., Deininger, M. W., Collins, et al
2017

- **Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?** *Haematologica*
Medeiros, B. C.
2017; 102 (8): 1301–3
- **Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.** *Leukemia*
DeAngelo, D. J., George, T. I., Linder, A. n., Langford, C. n., Perkins, C. n., Ma, J. n., Westervelt, P. n., Merker, J. D., Berube, C. n., Coutre, S. n., Liedtke, M. n., Medeiros, B. n., Sternberg, et al
2017
- **Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide or azacitidine in persons #65 years with newly-diagnosed acute myeloid leukemia.** *Haematologica*
Medeiros, B. C., McCaul, K. n., Kambhampati, S. n., Pollyea, D. A., Kumar, R. n., Silverman, L. R., Kew, A. n., Saini, L. n., Beach, C. L., Vij, R. n., Wang, X. n., Zhong, J. n., Gale, et al
2017
- **Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Østgård, L. S., Nørgaard, M. n., Medeiros, B. C., Friis, L. S., Schoellkopf, C. n., Severinsen, M. T., Marcher, C. W., Nørgaard, J. M.
2017: JCO2017736728
- **Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.** *JAMA oncology*
Sorrer, M. L., Storer, B. E., Fathi, A. T., Gerds, A. T., Medeiros, B. C., Shami, P. n., Brunner, A. M., Sekeres, M. A., Mukherjee, S. n., Peña, E. n., Elsayy, M. n., Wardyn, S. n., Whitten, et al
2017
- **Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.** *Haematologica*
Walter, R. B., Othus, M. n., Orlowski, K. F., McDaniel, E. N., Scott, B. L., Becker, P. S., Percival, M. M., Hendrie, P. C., Medeiros, B. C., Chiarella, M. T., Louie, A. C., Estey, E. H.
2017
- **Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National Population-Based Cohort Study.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Østgård, L. S., Lund, J. L., Nørgaard, J. M., Nørgaard, M. n., Medeiros, B. C., Nielsen, B. n., Nielsen, O. J., Overgaard, U. M., Kallenbach, M. n., Marcher, C. W., Riis, A. H., Sengeløv, H. n.
2017
- **Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation.** *JAAD case reports*
Amitay-Laish, I. n., Sundram, U. n., Hoppe, R. T., Hodak, E. n., Medeiros, B. C., Kim, Y. H.
2017; 3 (4): 310–15
- **Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function.** *Cancer research*
Zhang, H. n., Means, S. n., Schultz, A. R., Watanabe-Smith, K. n., Medeiros, B. C., Bottomly, D. n., Wilmot, B. n., McWeeney, S. K., Kükenshöner, T. n., Hantschel, O. n., Tyner, J. W.
2017
- **Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat**
Pagel, J. M., Othus, M., Garcia-Manero, G., Fang, M., Radich, J. P., Rizzieri, D. A., Marcucci, G., Strickland, S. A., Litzow, M., Savoie, M., Spellman, S. R., Confer, D. L., Chell, et al
AMER SOC HEMATOLOGY.2016
- **Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models**
Sorrer, M. L., Storer, B. E., Elsayy, M., Fathi, A. T., Brunner, A. M., Gerds, A. T., Sekeres, M. A., Mukherjee, S., Medeiros, B. C., Wang, E. S., Vachhani, P., Shami, P. J., Pena, et al
AMER SOC HEMATOLOGY.2016
- **A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit**
Manero, G., Atallah, E., Khaled, S. K., Arellano, M., Patnaik, M. M., Odenike, O., Sayar, H., Tummala, M., Patel, P. A., Ghalie, R. G., Medeiros, B. C.

AMER SOC HEMATOLOGY.2016

- **Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial**
Lancet, J. E., Hoering, A., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., Stone, R. M., Bixby, et al
AMER SOC HEMATOLOGY.2016
- **SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA plus V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)**
Garcia-Manero, G., Othus, M., Pagel, J. M., Radich, J. P., Fang, M., Rizzieri, D. A., Marcucci, G., Strickland, S. A., Litzow, M., Savoie, M., Medeiros, B. C., Sekeres, M. A., Lin, et al
AMER SOC HEMATOLOGY.2016
- **Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial**
Medeiros, B. C., Lancet, J. E., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., Stone, R. M., Bixby, D. L., Kolitz, et al
AMER SOC HEMATOLOGY.2016
- **NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016.** *Journal of the National Comprehensive Cancer Network*
VanderWalde, N., Jagsi, R., Dotan, E., Baumgartner, J., Browner, I. S., Burhenn, P., Cohen, H. J., Edil, B. H., Edwards, B., Extermann, M., Ganti, A. K., Gross, C., Hubbard, et al
2016; 14 (11): 1357-1370
- **NCCN Guidelines (R) Insights Older Adult Oncology, Version 2.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
VanderWalde, N., Jagsi, R., Dotan, E., Baumgartner, J., Browner, I. S., Burhenn, P., Cohen, H. J., Edil, B. H., Edwards, B., Extermann, M., Ganti, A. K., Gross, C., Hubbard, et al
2016; 14 (11): 1357-1370
- **Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.** *Oncotarget*
Huang, M., Garcia, J. S., Thomas, D., Zhu, L., Nguyen, L. X., Chan, S. M., Majeti, R., Medeiros, B. C., Mitchell, B. S.
2016
- **Optimizing infusion scheduling through lean methods and data science.**
Medeiros, B. C., Healy, D., Seshadri, S., Rosenthal, E., Martin, J., Giridharadas, M., Cassidy, H., DeMarco, S.
AMER SOC CLINICAL ONCOLOGY.2016
- **Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.**
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S., Hogge, D., Solomon, S. R., Stone, R. M., Bixby, D. L., Kolitz, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.** *Leukemia*
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., Bangs, C. D., Cherry, A. M., Arai, S., Arber, D. A., Zehnder, J. L., Gotlib, J.
2016; 30 (4): 947-950
- **A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.** *British journal of haematology*
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., Berube, C., Medeiros, B. C., Liedtke, M.
2016; 173 (2): 253-259
- **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome** *LEUKEMIA & LYMPHOMA*
Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
2016; 57 (3): 609-615
- **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.** *Leukemia & lymphoma*

Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
2016; 57 (3): 609-615

- **Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies** *BLOOD*
Lewinsohn, M., Brown, A. L., Weinel, L. M., Phung, C., Rafidi, G., Lee, M. K., Schreiber, A. W., Feng, J., Babic, M., Chong, C., Lee, Y., Yong, A., Suthers, et al
2016; 127 (8): 1017-1023
- **Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.** *Biology of blood and marrow transplantation*
Pasquini, M. C., Zhang, M., Medeiros, B. C., Armand, P., Hu, Z., Nishihori, T., AlJurf, M. D., Akpek, G., Cahn, J., Cairo, M. S., Cerny, J., Copelan, E. A., Deol, et al
2016; 22 (2): 248-257
- **Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study.** *British journal of haematology*
Abrahão, R. n., Keogh, R. H., Lichtensztajn, D. Y., Marcos-Gragera, R. n., Medeiros, B. C., Coleman, M. P., Ribeiro, R. C., Keegan, T. H.
2016
- **Real-World Treatment Patterns and Outcomes among Elderly Acute Myeloid Leukemia Patients in the United States** *BIG DATA ON REAL-WORLD APPLICATIONS*
Satram-Hoang, S., Reyes, C., Hurst, D., Hoang, K. Q., Medeiros, B. C., Soto, S. V., Luna, J. M., Cano, A.
2016: 23–40
- **Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response.** *Scientific reports*
Jiang, D., Lynch, C., Medeiros, B. C., Liedtke, M., Bam, R., Tam, A. B., Yang, Z., Alagappan, M., Abidi, P., Le, Q., Giaccia, A. J., Denko, N. C., Niwa, et al
2016; 6: 33353-?
- **Why do subjects on clinical trials discontinue therapy? Do we really know?** *Leukemia research*
Medeiros, B. C., Gale, R. P.
2016; 51: 19–21
- **Management of invasive Aspergillosis in acute myelogenous leukemia.** *Clinical advances in hematology & oncology : H&O*
Medeiros, B. C.
2016; 14 (7): 502–4
- **Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach.** *Oncology (Williston Park, N.Y.)*
Jonas, B. A., Medeiros, B. C.
2016; 30 (4)
- **Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality**
Sorrer, M. L., Storer, B. E., Elsayy, M., Fathi, A. T., Brunner, A., Gerds, A. T., Sekeres, M. A., Mukherjee, S., Medeiros, B. C., Shami, P., Pena, E., Wardyn, S., Whitten, et al
AMER SOC HEMATOLOGY.2015
- **A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia**
DeAngelo, D. J., Walker, A. R., Schlenk, R. F., Sierra, J., Medeiros, B. C., Ocio, E. M., Roellig, C., Strickland, S. A., Thol, F., Valera, S., Wegener, A., De, T., Mu, et al
AMER SOC HEMATOLOGY.2015
- **The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance])**
Stone, R. M., Mandrekar, S., Sanford, B. L., Geyer, S., Bloomfield, C. D., Dohner, K., Thiede, C., Marcucci, G., Lo-Coco, F., Klisovic, R. B., Wei, A., Sierra, J., Sanz, et al
AMER SOC HEMATOLOGY.2015
- **Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial**
Stein, E. M., DiNardo, C., Altman, J. K., Collins, R., DeAngelo, D. J., Kantarjian, H. M., Sekeres, M. A., Fathi, A. T., Flinn, I. W., Frankel, A. E., Levine, R. L., Medeiros, B. C., Patel, et al

AMER SOC HEMATOLOGY.2015

- **Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)**
Garcia-Manero, G., Atallah, E., Khaled, S. K., Arellano, M., Patnaik, M. M., Butler, T. A., Ashby, C., Medeiros, B. C.
AMER SOC HEMATOLOGY.2015
- **Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study**
Abraham, R., Keogh, R. H., Lichtensztajn, D. Y., Marcos-Gragera, R., Medeiros, B. C., Coleman, M. I., Ribeiro, R. C., Keegan, T. M.
AMER SOC HEMATOLOGY.2015
- **Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.** *Cancer discovery*
Behbehani, G. K., Samusik, N., Bjornson, Z. B., Fantl, W. J., Medeiros, B. C., Nolan, G. P.
2015; 5 (9): 988-1003
- **Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States** *ANNALS OF HEMATOLOGY*
Medeiros, B. C., Satram-Hoang, S., Hurst, D., Hoang, K. Q., Momin, F., Reyes, C.
2015; 94 (7): 1127-1138
- **Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis** *CANCER*
Percival, M. M., Tao, L., Medeiros, B. C., Clarke, C. A.
2015; 121 (12): 2004-2012
- **Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study** *BRITISH JOURNAL OF HAEMATOLOGY*
Swords, R. T., Erba, H. P., DeAngelo, D. J., Bixby, D. L., Altman, J. K., Maris, M., Hua, Z., Blakemore, S. J., Faessel, H., Sedarati, F., Dezube, B. J., Giles, F. J., Medeiros, et al
2015; 169 (4): 534-543
- **G-CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm** *AMERICAN JOURNAL OF HEMATOLOGY*
Becker, P. S., Medeiros, B. C., Stein, A. S., Othus, M., Appelbaum, F. R., Forman, S. J., Scott, B. L., Hendrie, P. C., Gardner, K. M., Pagel, J. M., Walter, R. B., Parks, C., Wood, et al
2015; 90 (4): 295-300
- **Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.** *Haematologica*
Medeiros, B. C., Othus, M., Fang, M., Appelbaum, F. R., Erba, H. P.
2015; 100 (3): 331-335
- **Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.** *Nature medicine*
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W., Zhao, F., Medeiros, B. C., Tyvoll, D. A., Majeti, R.
2015; 21 (2): 178-184
- **Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia** *NATURE MEDICINE*
Chan, S. M., Thomas, D., Corces-Zimmerman, M. R., Xavy, S., Rastogi, S., Hong, W., Zhao, F., Medeiros, B. C., Tyvoll, D. A., Majeti, R.
2015; 21 (2): 90-96
- **Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.** *Human pathology*
Rakheja, D., Fuda, F., Vandergriff, T., Boriack, R., Medeiros, B. C., Frankel, A. E., Chen, W.
2015; 46 (2): 322-326
- **Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.** *Bone marrow transplantation*
Percival, M. M., Medeiros, B. C., Tian, L. n., Robeson, S. n., Laport, G. G., Johnston, L. J., Shizuru, J. A., Miklos, D. B., Arai, S. n., Weng, W. K., Negrin, R. S., Lowsky, R. n.
2015
- **Chemotherapy options for previously untreated acute myeloid leukemia** *EXPERT OPINION ON PHARMACOTHERAPY*
Lynch, R. C., Medeiros, B. C.
2015; 16 (14): 2149-2162

- **Chemotherapy dose in obese AML patients: To cap or not to cap?** *LEUKEMIA RESEARCH*
Percival, M. M., Medeiros, B. C.
2015; 39 (1): 30-32
- **Monosomal karyotype acute myeloid leukemia: tread lightly.** *Acta haematologica*
Garcia, J. S., Medeiros, B. C.
2015; 133 (4): 324-326
- **Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California.** *Cancer*
Abrahão, R. n., Ribeiro, R. C., Medeiros, B. C., Keogh, R. H., Keegan, T. H.
2015
- **Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.** *Leukemia*
Khalife, J. n., Radomska, H. S., Santhanam, R. n., Huang, X. n., Neviani, P. n., Saultz, J. n., Wang, H. n., Wu, Y. Z., Alachkar, H. n., Anghelina, M. n., Dorrance, A. n., Curfman, J. n., Bloomfield, et al
2015
- **Preclinical Activity of a New Proteasome Inhibitor, MLN9708, in Acute Myelogenous Leukemias Expressing NPM1 Mutated Protein**
Garcia, J. S., Huang, M., Medeiros, B. C., Mitchell, B. S.
AMER SOC HEMATOLOGY.2014
- **AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies**
Stein, E. M., Altman, J. K., Collins, R., DeAngelo, D. J., Fathi, A. T., Flinn, I., Frankel, A., Levine, R. L., Medeiros, B. C., Patel, M., Pollyea, D. A., Roboz, G. J., Stone, et al
AMER SOC HEMATOLOGY.2014
- **Isocitrate Dehydrogenase Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia through Inhibition of Cytochrome C Oxidase Function**
Chan, S. M., Thomas, D., Medeiros, B. C., Majeti, R.
AMER SOC HEMATOLOGY.2014
- **Big Data Analysis of Treatment Patterns and Outcomes Among Elderly Medicare Acute Myeloid Leukemia Patients**
Satram-Hoang, S., Reyes, C., Hoang, K. Q., Momin, F., Hurst, D., Medeiros, B. C.
AMER SOC HEMATOLOGY.2014
- **Improvements in the Early Death Rate in Younger Acute Myeloid Leukemia Patients Following Initial Therapy: A SEER Database Analysis**
Percival, M. M., Tao, L., Medeiros, B. C., Clarke, C. A.
AMER SOC HEMATOLOGY.2014
- **Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Cell Cycle Properties That Correlate with Known Responses to Chemotherapy**
Behbehani, G. K., Fantl, W. J., Medeiros, B. C., Nolan, G. P.
AMER SOC HEMATOLOGY.2014
- **Mass Cytometric Analysis of AML Stem and Early Progenitor Cells Reveals Karyotype and Genotype-Specific Immunophenotypes That May Represent Targets for Antibody-Directed Therapies**
Behbehani, G. K., Fantl, W. J., Medeiros, B. C., Nolan, G. P.
AMER SOC HEMATOLOGY.2014
- **Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial**
Swords, R. T., Savona, M. R., Maris, M. B., Erba, H. P., Berdeja, J. G., Foran, J. M., Hua, Z., Faessel, H. M., Dash, A. B., Sedarati, F., Dezube, B. J., Medeiros, B. C.
AMER SOC HEMATOLOGY.2014
- **Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)**
Garcia-Manero, G., Atallah, E., Odenike, O., Medeiros, B. C., Cortes, J. E., Esquibel, V., Cha, S., Khaled, S. K.
AMER SOC HEMATOLOGY.2014

- **Comparative Effectiveness of Chemotherapy in an Elderly Acute Myeloid Leukemia Population in the United States**
Medeiros, B. C., Satram-Hoang, S., Hoang, K. Q., Momin, F., Hurst, D., Reyes, C.
AMER SOC HEMATOLOGY.2014
- **Real-World Outcomes Among Elderly Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation**
Medeiros, B. C., Satram-Hoang, S., Hoang, K. Q., Momin, F., Hurst, D., Reyes, C.
AMER SOC HEMATOLOGY.2014
- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia** *LEUKEMIA RESEARCH*
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berube, C., Gotlib, J., Patel, S., Medeiros, B.
2014; 38 (12): 1441-1445
- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.** *Leukemia research*
Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., Patel, S., Medeiros, B.
2014; 38 (12): 1441-1445
- **Polypharmacy in AML: the tip of the iceberg.** *Leukemia research*
Patel, S., Medeiros, B. C.
2014; 38 (11): 1378-1379
- **Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells (vol 9, e93530, 2014)** *PLOS ONE*
Xu, G. W., Toth, J., da Silva, S. R., Paiva, S., Lukkarila, J. L., Medeiros, B.
2014; 9 (10)
- **Management considerations in older patients with AML: a 2014 perspective.** [*Rinsho ketsueki*] *The Japanese journal of clinical hematology*
Medeiros, B. C.
2014; 55 (10): 1803-1807
- **Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.** *Blood*
Frankel, A. E., Woo, J. H., Ahn, C., Pemmaraju, N., Medeiros, B. C., Carraway, H. E., Frankfurt, O., Forman, S. J., Yang, X. A., Konopleva, M., Garnache-Ottou, F., Angelot-Delettire, F., Brooks, et al
2014; 124 (3): 385-392
- **Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia** *LEUKEMIA RESEARCH*
Pierceall, W. E., Lena, R. J., Medeiros, B. C., Blake, N., Doykan, C., Elashoff, M., Cardone, M. H., Walter, R. B.
2014; 38 (5): 564-568
- **European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation** *BLOOD CANCER JOURNAL*
Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., Miklos, D. B., Arai, S., Benjamin, J. E., Weng, W., Negrin, R. S., Lowsky, R.
2014; 4
- **Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells** *PLOS ONE*
Xu, G. W., Toth, J. I., da Silva, S. R., Paiva, S., Lukkarila, J. L., Hurren, R., Maclean, N., Sukhai, M. A., Bhattacharjee, R. N., Goard, C. A., Gunning, P. T., dhe-Paganon, S., Petroski, et al
2014; 9 (4)
- **Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*
Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., Appelbaum, F. R.
2014; 164 (2): 245-250
- **Consolidation therapy in acute myeloid leukemia** *CANCER CONSULT: EXPERTISE FOR CLINICAL PRACTICE*
Behbehani, G. K., Medeiros, B. C., Abutalib, S. A., Markman, M.
2014: 67-70
- **Senior Adult Oncology, Version 2.2014** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Hurria, A., Wildes, T., Blair, S. L., Browner, I. S., Cohen, H. J., deShazo, M., Dotan, E., Edil, B. H., Extermann, M., Ganti, A. K., Holmes, H. M., Jagsi, R., Karlekar, et al
2014; 12 (1): 82-126

- **Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia.** *Acta haematologica*
Medeiros, B. C.
2014; 131 (4): 200-201
- **Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study** *HAEMATOLOGICA*
Walter, R. B., Medeiros, B. C., Gardner, K. M., Orlowski, K. F., Gallegos, L., Scott, B. L., Hendrie, P. C., Estey, E. H.
2014; 99 (1): 54-59
- **Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Older Adults: Geriatric Principles in the Transplant Clinic** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Wildes, T. M., Stirewalt, D. L., Medeiros, B., Hurria, A.
2014; 12 (1): 128-136
- **Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .** *Journal of the National Comprehensive Cancer Network*
Hurria, A., Wildes, T., Blair, S. L., Browner, I. S., Cohen, H. J., deShazo, M., Dotan, E., Edil, B. H., Extermann, M., Ganti, A. K., Holmes, H. M., Jagsi, R., Karlekar, et al
2014; 12 (1): 82-126
- **Qualitative analysis of practicing oncologists' attitudes and experiences regarding collection of patient-reported outcomes.** *Journal of oncology practice / American Society of Clinical Oncology*
Jagsi, R., Chiang, A., Polite, B. N., Medeiros, B. C., McNiff, K., Abernethy, A. P., Zon, R., Loehrer, P. J.
2013; 9 (6): e290-7
- **Qualitative Analysis of Practicing Oncologists' Attitudes and Experiences Regarding Collection of Patient-Reported Outcomes** *JOURNAL OF ONCOLOGY PRACTICE*
Jagsi, R., Chiang, A., Polite, B. N., Medeiros, B. C., McNiff, K., Abernethy, A. P., Zon, R., Loehrer, P. J.
2013; 9 (6): E290–E297
- **A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.** *Leukemia & lymphoma*
Patel, S., Liedtke, M., Ngo, D., Medeiros, B. C.
2013; 54 (10): 2231-2235
- **Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.** *Haematologica*
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., Greenberg, P., Zhang, B., Liedtke, M., Berube, C., Levine, R., Mitchell, B. S., Medeiros, et al
2013; 98 (4): 591-596
- **CD11b expression and MK+ AML: A sign of impending doom?** *LEUKEMIA RESEARCH*
Medeiros, B. C.
2013; 37 (2): 121-121
- **2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels** *LEUKEMIA & LYMPHOMA*
Pollyea, D. A., Kohrt, H. E., Zhang, B., Zehnder, J., Schenkein, D., Fantin, V., Straley, K., Vasanthakumar, A., Abdel-Wahab, O., Levine, R., Godley, L. A., Medeiros, B. C.
2013; 54 (2): 408-410
- **CD19(-)CD45(low-)/CD38(high)/CD138(+) plasma cells enrich for human tumorigenic myeloma cells** *LEUKEMIA*
Kim, D., Park, C. Y., Medeiros, B. C., Weissman, I. L.
2012; 26 (12): 2530-2537
- **Qualitative analysis of practicing oncologists' attitudes and experiences regarding HIT-facilitated collection of patientreported outcomes**
Jagsi, R., Chiang, A. C., Medeiros, B. C., Polite, B. N., McNiff, K., Zon, R., Loehrer, P. J.
AMER SOC CLINICAL ONCOLOGY.2012
- **Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Dose-Escalation Study** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., Liedtke, M.
AMER SOC HEMATOLOGY.2012

- **Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy**
Pollyea, D. A., Zehnder, J. L., Coutre, S., Gotlib, J., Gallegos, L., Greenberg, P., Zhang, B., Liedtke, M., Levine, R. L., Medeiros, B. C.
AMER SOC HEMATOLOGY.2012
- **Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study**
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., Liedtke, M.
AMER SOC HEMATOLOGY.2012
- **Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Becker, P. S., Medeiros, B. C., Stein, A. S., Appelbaum, F. R., Scott, B. L., Delaney, C., Othus, M., Hendrie, P. C., Gardner, K. M., Petersdorf, S., Pagel, J. M., Walter, R. B., Parks, et al
AMER SOC HEMATOLOGY.2012
- **A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Medeiros, B. C., Liedtke, M.
AMER SOC HEMATOLOGY.2012
- **Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options** *HEMATOLOGY*
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., Liedtke, M.
2012; 17 (6): 325-328
- **Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., Djulbegovic, B., Faber, E. A., Gasparetto, C., Hernandez-Ilizaliturri, F., Huff, C. A., Kassim, A., Krishnan, et al
2012; 10 (10): 1211-1219
- **Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.** *Journal of the National Comprehensive Cancer Network*
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., Djulbegovic, B., Faber, E. A., Gasparetto, C., Hernandez-Ilizaliturri, F., Huff, C. A., Kassim, A., Krishnan, et al
2012; 10 (10): 1211-1219
- **Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., Bates, J., Sekeres, M. A., Coutre, S., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al
2012; 87 (10): 957-960
- **Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Medeiros, B. C., Othus, M., Estey, E. H., Fang, M., Appelbaum, F. R.
2012; 97 (9): 1401-1404
- **Novel agents in acute myeloid leukemia** *INTERNATIONAL JOURNAL OF HEMATOLOGY*
Ungewickell, A., Medeiros, B. C.
2012; 96 (2): 178-185
- **New treatment approaches for older adults with multiple myeloma** *JOURNAL OF GERIATRIC ONCOLOGY*
Wildes, T. M., Vij, R., Petersdorf, S. H., Medeiros, B. C., Hurria, A.
2012; 3 (3): 279-290
- **Blood consult: monosomal karyotype acute myeloid leukemia** *BLOOD*
Garcia, J. S., Medeiros, B. C., Appelbaum, F. R.
2012; 119 (24): 5659-5660
- **Impact of residual normal metaphases in core binding factor acute myeloid leukemia** *CANCER*
Medeiros, B. C., Othus, M., Fang, M., Appelbaum, F. R., Estey, E. H.
2012; 118 (9): 2420-2423

- **Aggressive EBV-associated Lymphoproliferative Disorder: A Prodrome to Diffuse Large B-cell Lymphoma?** *APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY*
Batra, R., Medeiros, B. C., Zehnder, J. L., Warnke, R. A., Natkunam, Y.
2012; 20 (3): 325-330
- **Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Walter, R. B., Medeiros, B. C., Powell, B. L., Schiffer, C. A., Appelbaum, F. R., Estey, E. H.
2012; 97 (5): 739-742
- **Unveiling the complexity of CK+ AML.** *Blood*
Medeiros, B. C.
2012; 119 (9): 1958-1959
- **"It doesn't matter if you're black or white", does it?** *LEUKEMIA RESEARCH*
Medeiros, B. C.
2012; 36 (2): 127-127
- **Senior Adult Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Hurria, A., Browner, I. S., Cohen, H. J., Denlinger, C. S., deShazo, M., Extermann, M., Ganti, A. K., Holland, J. C., Holmes, H. M., Karlekar, M. B., Keating, N. L., Mckoy, J., Medeiros, et al
2012; 10 (2): 162-209
- **Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., Arber, D. A., Zehnder, J. L.
2012; 87 (1): 45-50
- **Treatment advances have not improved the early death rate in acute promyelocytic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., Medeiros, B. C.
2012; 97 (1): 133-136
- **Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., Bhat, N. M., Teng, N. N., Coutre, S. E.
2012; 97 (1): 30-37
- **Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Becker, P. S., Medeiros, B. C., Appelbaum, F. R., Scott, B. L., Hendrie, P. C., Storer, B., Pierce, S., Petersdorf, S. H., Estey, E. H.
AMER SOC HEMATOLOGY.2011: 1545-45
- **Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia**
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A. A., Bates, J., Sekeres, M. A., Coutre, S. E., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al
AMER SOC HEMATOLOGY.2011: 1095
- **Gemtuzumab Ozogamicin in Combination with Vorinostat and Azacitidine As Induction and Post-Remission Therapy in Older Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase 1 Study**
Walter, R. B., Medeiros, B. C., Gardner, K. M., Estey, E. H.
AMER SOC HEMATOLOGY.2011: 670
- **2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels**
Pollyea, D. A., Kohrt, H. E., Zhang, B., Zehnder, J. L., Schenkein, D. P., Fantin, V., Straley, K., Vasanthakumar, A., Abdel-Wahab, O., Levine, R. L., Godley, L., Medeiros, B. C.
AMER SOC HEMATOLOGY.2011: 1073-74
- **Multiple Myeloma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*

Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., Devine, S., Djulbegovic, B., Faber, E. A., Gasparetto, C., Huff, C. A., Kassim, A., Medeiros, et al
2011; 9 (10): 1146-1183

- **Personalized medicine for acute myelogenous leukemia-At the entrance gate** *AMERICAN JOURNAL OF HEMATOLOGY*
Swords, R. T., Dezube, B. J., Medeiros, B. C.
2011; 86 (8): 631-32
- **Cytarabine Dose for Acute Myeloid Leukemia** *NEW ENGLAND JOURNAL OF MEDICINE*
Mori, J., Tsubokura, M., Kami, M.
2011; 364 (22): 2166-67
- **Unfavorable-risk cytogenetics in acute myeloid leukemia** *EXPERT REVIEW OF HEMATOLOGY*
Hong, W., Medeiros, B. C.
2011; 4 (2): 173-184
- **Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Xie, B., Othus, M., Medeiros, B. C., Fang, M., Appelbaum, F. R., Estey, E. H.
2011; 96 (4): 631-32
- **Acute myeloid leukaemia in the elderly: a review** *BRITISH JOURNAL OF HAEMATOLOGY*
Pollyea, D. A., Kohrt, H. E., Medeiros, B. C.
2011; 152 (5): 524-542
- **Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer** *EXPERT OPINION ON THERAPEUTIC TARGETS*
Wang, M., Medeiros, B. C., Erba, H. P., DeAngelo, D. J., Giles, F. J., Swords, R. T.
2011; 15 (3): 253-264
- **Microfluidic purification and analysis of hematopoietic stem cells from bone marrow** *LAB ON A CHIP*
Schirhagl, R., Fuereder, I., Hall, E. W., Medeiros, B. C., Zare, R. N.
2011; 11 (18): 3130-3135
- **A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., Liedtke, M., Mitchell, B. S., Medeiros, B. C.
AMER SOC HEMATOLOGY.2010: 1347-47
- **Update of a Phase I/II Trial of 5-Azacitidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies**
Ball, E. D., Medeiros, B. C., Balaian, L., Roque, T., Corringham, S., Rajwanshi, R., Coutre, S., Gotlib, J. R., Bashey, A., Messer, K.
AMER SOC HEMATOLOGY.2010: 1346
- **The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study**
Swords, R. T., Erba, H. P., DeAngelo, D. J., Smith, P. G., Pickard, M. D., Dezube, B. J., Giles, F. J., Medeiros, B. C.
AMER SOC HEMATOLOGY.2010: 288
- **Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype.**
Xie, B., Othus, M., Medeiros, B. C., Fang, M., Appelbaum, F. R., Estey, E. H.
AMER SOC HEMATOLOGY.2010: 701
- **Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Zhang, M., Arber, D. A., Zehnder, J. L.
AMER SOC HEMATOLOGY.2010: 1357-58
- **Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience** *AMERICAN JOURNAL OF HEMATOLOGY*
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Alizadeh, A. A., Medeiros, B. C.
2010; 85 (11): 877-881

- **Plasma cell leukemia: concepts and management.** *Expert review of hematology*
Liedtke, M., Medeiros, B. C.
2010; 3 (5): 543-549
- **Plasma cell leukemia: concepts and management** *EXPERT REVIEW OF HEMATOLOGY*
Liedtke, M., Medeiros, B. C.
2010; 3 (5): 539-549
- **Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge** *AMERICAN JOURNAL OF HEMATOLOGY*
Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., Cherry, A., Corless, C., Arber, D. A., Valent, P., George, T. I.
2010; 85 (8): 600-606
- **PHASE 2 TRIAL OF VORINOSTAT (SAHA) IN COMBINATION WITH GEMTUZUMAB OZOGAMICIN AS INDUCTION AND POST-REMISSION THERAPY IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA (AML)** *15th Annual Meeting of the European-Hematology-Association*
Walter, B., Medeiros, B., Nielsen-Stoeck, M., Harrington, E., Powell, B., Schiffer, C., Appelbaum, F., Estey, E.
FERRATA STORTI FOUNDATION.2010: 29–30
- **Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)** *LEUKEMIA RESEARCH*
Medeiros, B. C., Kohrt, H. E., Arber, D. A., Bangs, C. D., Cherry, A. M., Majeti, R., Kogel, K. E., Azar, C. A., Patel, S., Alizadeh, A. A.
2010; 34 (5): 594-597
- **Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., Medeiros, B. C.
AMER SOC HEMATOLOGY.2009: 420–21
- **The PI3K Inhibitor GDC-0941 Induces Growth Arrest and Apoptosis of Acute Myeloid Leukemia Cells**
Sun, L., Berry, L., Du, C., Ma, X., Shi, L., Medeiros, B. C., Ebens, A. J.
AMER SOC HEMATOLOGY.2009: 1456
- **High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis.**
Logan, A. C., Su, R., George, T. I., Kohrt, H. E., Medeiros, B. C., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2009: 554
- **A Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies.**
Ball, E. D., Medeiros, B. C., Balaian, L., Roque, T., Corringham, S., Rajwanshi, R., Coutre, S., Gotlib, J. R., Bashey, A., Messer, K.
AMER SOC HEMATOLOGY.2009: 809
- **Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., Coutre, S., Medeiros, B. C., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2009: 646–47
- **Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy** *AMERICAN JOURNAL OF HEMATOLOGY*
Pretz, J., Medeiros, B. C.
2009; 84 (10): 698-699
- **NCCN clinical practice guidelines in oncology: multiple myeloma.** *Journal of the National Comprehensive Cancer Network*
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., Devine, S., Djulbegovic, B., Gasparetto, C., Huff, C. A., Jagasia, M., Medeiros, B. C., Meredith, et al
2009; 7 (9): 908-942
- **Multiple Myeloma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, S., Chanan-Khan, A., Cohen, A. D., Devine, S., Djulbegovic, B., Gasparetto, C., Huff, C. A., Jagasia, M., Medeiros, B. C., Meredith, et al
2009; 7 (9): 908-942

- **Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., Rajwanshi, R., Zehnder, J., Zehnder, J.
AMER SOC CLINICAL ONCOLOGY.2009
- **Baseline status of O (6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and effect of protracted doses of temozolomide on MGMT in acute leukemia.**
Medeiros, B., Khan, S., Rajwanshi, R., Jones, C., Zehnder, J.
AMER ASSOC CANCER RESEARCH.2009
- **CD38(hi)CD138(+) bone marrow cells from multiple myeloma patients engraft into human bone microenvironments in humanized mice.**
Kim, D., Medeiros, B., Weissman, I.
AMER ASSOC CANCER RESEARCH.2009
- **Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia** *NEW ENGLAND JOURNAL OF MEDICINE*
Medeiros, B. C.
2009; 360 (17): 1787-1787
- **Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
Medeiros, B. C.
2009; 27 (12): 2105-2105
- **Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
Medeiros, B. C.
2009; 27 (3): 474-474
- **Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.** *Cases journal*
Chan, S. M., George, T., Cherry, A. M., Medeiros, B. C.
2009; 2 (1): 121-?
- **Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission** *LEUKEMIA & LYMPHOMA*
Medeiros, B. C., Gotlib, J., Zehnder, J.
2009; 50 (5): 851-853
- **Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study** *98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., Corless, C., Arber, D. A., George, T. I.
NATURE PUBLISHING GROUP.2009: 277A-277A
- **Tailored Temozolomide Therapy for Elderly Patients with Acute Myeloid Leukemia.**
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Mignea, A., Zehnder, J.
AMER SOC HEMATOLOGY.2008: 351
- **Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma** *LEUKEMIA & LYMPHOMA*
Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., Medeiros, B.
2008; 49 (3): 581-585
- **Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation** *AMERICAN JOURNAL OF HEMATOLOGY*
Medeiros, B. C., Chun, K., Kamel-Reid, S., Lipton, J.
2007; 82 (8): 758-760
- **Absence of FTL3 mutations in patients with JAK2(V617F) mutation negative essential thrombocythemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Medeiros, B. C., Zhang, T., Lipton, J. H., Kamel-Reid, S.
2007; 82 (4): 293-294
- **Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (> 5 years)** *LEUKEMIA & LYMPHOMA*
Medeiros, B. C., Minden, M. D., Schuh, A. C., Schimmer, A. D., Yee, K., Lipton, J. H., Messner, H. A., Gupta, V., Chun, K., Xu, W., Das, P., Kamel-Reid, S., Brandwein, et al

2007; 48 (1): 65-71

- **Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose Interleukin-2 for treatment of metastatic renal cell carcinoma** *TRANSFUSION AND APHERESIS SCIENCE*

Medeiros, B. C., Kogel, K. E., Kane, M. A.

2003; 29 (1): 25-27